621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study is significant because Semaglutide, a GLP-1 receptor agonist, is already approved for obesity and type 2 diabetes, conditions strongly linked to NAFLD. If the results demonstrate efficacy, it could provide …
The resurgence of cocaine use and related mortality underscores an urgent, unmet need for effective treatments. If Semaglutide proves effective in this pilot study, it could offer a novel pharmacological approach to C…
This study holds significant promise for identifying a novel therapeutic approach for alcohol use disorder (AUD), especially in the context of obesity and fatty liver disease, which are highly prevalent comorbidities.…
This research could fundamentally change our understanding of how GLP-1 RAs exert their metabolic benefits, extending beyond peripheral tissues to direct brain mechanisms. By clarifying the role of semaglutide in enha…
If the anticipated findings are confirmed, this study could provide crucial evidence for the broad metabolic benefits of GLP-1RAs beyond just glycemic control and weight loss. A detailed understanding of how these dru…
As this is a planned study, no results are available yet. However, the researchers anticipate that CagriSema will demonstrate significant improvements in key metabolic markers compared to placebo.
This Phase II IMPACT-ADT trial is profoundly important as it directly addresses a major unmet need in prostate cancer survivorship, aiming to mitigate the severe cardiometabolic side effects of Androgen Deprivation Th…
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
The potential to preserve lean mass during GLP-1 induced weight loss is crucial for improving long-term health outcomes and metabolic function in individuals with obesity. Preventing muscle loss can enhance strength, …
This study is critically important as it will provide a head-to-head comparison of the most effective current treatments for obesity, offering invaluable data for clinical decision-making. If Semaglutide or Tirzepatid…
The findings of this study are crucial for enhancing patient safety during surgical procedures for individuals on GLP-1/GIP agonists. If standard fasting guidelines prove insufficient, it could lead to revised pre-ope…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
This head-to-head Phase 3 trial is critically important because it directly compares retatrutide, a potential best-in-class GLP-1/GIP/Glucagon receptor triple-agonist, against semaglutide, a leading GLP-1 receptor ago…
Preventing muscle loss during significant weight reduction is critical for long-term health outcomes, as preserved muscle mass contributes to better metabolic function, strength, and overall quality of life. If succes…
This landmark study provides strong evidence that current recommendations for discontinuing GLP-1/GIP agonists before upper endoscopy may be overly cautious. The findings suggest that patients can safely continue thei…
This research provides crucial evidence that GLP-1 medicines offer a superior weight loss profile by effectively reducing fat mass while preserving vital muscle mass and function. This finding is particularly signific…
This comprehensive meta-analysis strongly reinforces Liraglutide's established role as an effective and safe treatment for T2DM, offering significant benefits beyond glycemic control, including clinically meaningful w…
This study offers crucial insights into the sociocultural dimensions of semaglutide use, extending beyond its pharmacological effects. Understanding the social stigma and public perceptions associated with medication-…
This research highlights a crucial, often overlooked, aesthetic side effect of rapid weight loss induced by GLP-1 RAs, which can significantly impact patient satisfaction and body image. Understanding this phenomenon …
This real-world study reinforces the significant cardiovascular protective effects of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in a diverse primary care population with Type 2 Diabetes. The findings provide cruci…
This study provides crucial real-world validation of semaglutide's effectiveness in a large Chinese population, reinforcing its role as a powerful therapeutic option for Type 2 Diabetes. The significant improvements i…
This meta-analysis provides critical evidence that while semaglutide is highly effective for many, a substantial subset of patients experiences suboptimal weight or glycemic improvements or discontinues therapy. This …
This review is critical for advancing the understanding and treatment of MASH, a disease with significant unmet medical needs. It provides a roadmap for developing more effective, patient-specific therapies, moving be…
This large-scale, real-world data provides crucial insights into the safety profile of GLP-1 receptor agonists when exposure occurs around conception. The reassurance regarding major congenital malformations is partic…
This comprehensive review provides crucial insights for clinicians prescribing GLP-1 receptor agonists, emphasizing the importance of considering potential ocular risks alongside the well-known benefits. The findings …
This study provides compelling evidence that GLP-1 RAs offer significant benefits beyond metabolic control, extending to crucial aspects of mental health and cognitive function. These findings suggest a potential for …
These pivotal Phase 3 trials definitively demonstrate that oral semaglutide 14 mg, at the tested dose and duration, is not an effective treatment for slowing cognitive decline in early symptomatic Alzheimer's disease.…
This research highlights the critical importance of considering sex as a biological variable in metabolic research and clinical practice. The observed protection in females against semaglutide-induced muscle loss coul…
This comprehensive update highlights that resmetirom, a selective thyroid hormone receptor-beta (THR-β) agonist, represents a groundbreaking advancement in the treatment of MASH. Its recent FDA approval as the first d…
The analysis revealed that a significant portion of media reports, approximately 45%, contained inaccuracies or presented information without adequate scientific context regarding the link between Semaglutide and NAIO…
This newly developed ECLIA offers a highly sensitive, specific, and robust platform for measuring semaglutide levels in human serum, significantly advancing analytical capabilities. Such a precise method is invaluable…
This study highlights the synergistic benefits of combining oral semaglutide with levothyroxine for patients suffering from both Type 2 Diabetes and hypothyroidism. The significant improvements in glycemic control, we…
This real-world evidence strongly supports the effectiveness and safety of oral semaglutide in a diverse Asian population, mirroring results from controlled clinical trials. The convenience of an oral formulation can …
This study highlights a significant barrier to effective patient education for widely used medications like semaglutide. Most online semaglutide patient education is inaccessible to the average person, potentially hin…
This study provides compelling evidence that oral semaglutide not only reduces major adverse cardiovascular events (as demonstrated in the primary SOUL trial) but also profoundly improves a wide array of individual ca…
This study provides compelling evidence that GLP-1 receptor agonists offer significant cardioprotective benefits beyond their established roles in glycemic control and weight management. The robust reduction in heart …
These findings provide critical, real-world insights into the sexual safety profiles of widely used antidiabetic medications, which are often missed in controlled clinical trials. This information is vital for healthc…
This review underscores the critical importance of early identification and aggressive management of MASLD in obese youth to mitigate the escalating risk of type 2 diabetes. Recognizing MASLD not just as a liver condi…
This study provides crucial real-world evidence supporting the safe and effective use of GLP-1 RAs in a vulnerable population previously lacking dedicated research. The observed improvements in glycemic control, weigh…
This systematic review underscores the urgent need for more comprehensive human data to guide clinical practice. Given the rising prevalence of obesity and type 2 diabetes in women of reproductive age, understanding t…